NCT06091865

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2023-12-13Est. Completion: 2028-03-30

Enrollment target: 904 participants

Locations

David Geffen School of Medicine at UCLA, Los Angeles, California, United States
University of California Irvine Medical Center, Orange, California, United States
University of California (UC) Davis, Sacramento, California, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
St Vincent Ascension at Peyton Manning Childrens Hospital, Indianapolis, Indiana, United States
Investigative Clinical Research of Indiana, Noblesville, Indiana, United States
University of Kentucky, Lexington, Kentucky, United States
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Henry Ford Health System, Detroit, Michigan, United States
Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Stony Brook University Hospital, Stony Brook, New York, United States
Clinical Research Alliance Inc, Westbury, New York, United States

Other microbiome trials you might be interested in

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell TherapyPhase 2Recruiting

Recurrent Diffuse Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

This phase II trial tests how well odronextamab works before and after standard of care (SOC) chimeric antigen receptor …

Sacramento, United StatesEst. completion Oct 2028

View Trial →

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesPhase 1Recruiting

Hematologic Cancer

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood …

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.